1. Home
  2. BTT vs TNDM Comparison

BTT vs TNDM Comparison

Compare BTT & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Municipal 2030 Target Term Trust

BTT

BlackRock Municipal 2030 Target Term Trust

HOLD

Current Price

$22.79

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$23.98

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTT
TNDM
Founded
2012
2006
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
BTT
TNDM
Price
$22.79
$23.98
Analyst Decision
Buy
Analyst Count
0
18
Target Price
N/A
$27.89
AVG Volume (30 Days)
109.4K
2.7M
Earning Date
01-01-0001
05-19-2026
Dividend Yield
2.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,014,736,000.00
Revenue This Year
N/A
$8.01
Revenue Next Year
N/A
$12.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.93
52 Week Low
$20.20
$10.00
52 Week High
$23.08
$29.65

Technical Indicators

Market Signals
Indicator
BTT
TNDM
Relative Strength Index (RSI) 47.46 58.27
Support Level $22.48 $19.66
Resistance Level $22.90 $24.23
Average True Range (ATR) 0.14 1.17
MACD -0.02 -0.06
Stochastic Oscillator 44.21 66.84

Price Performance

Historical Comparison
BTT
TNDM

About BTT BlackRock Municipal 2030 Target Term Trust

Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: